🔗 Share this article

Given that the United States proceeds with sweeping changes to its vaccine recommendations, an unexpected name appears in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on Covid shots throughout the global health crisis and has concentrated on possible deaths after Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Schedule

Agency leaders were set to unveil radical changes to the childhood immunization program in December, aligning the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US at odds with much of the international standard with insufficient data for improved outcomes. This reveal has been delayed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the meeting. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this calendar year.

Consolidating Power at the FDA

This interim role may indicate a closer partnership between the drug and vaccine centers as Høeg and Prasad consolidate power at the regulatory agency – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood vaccine recommendations in the US so as to align more in line with Denmark's approach, a society with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

In her initial comments, she has continued to focus on vaccines – usually the responsibility of Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Questions Over Background

Dr. Høeg has little discernible track record in drug development, oversight or management, which has been customary for former heads of the CBER. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She appears not to have any of the qualifications” for overseeing the CDER, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She is not versed in running a major agency. She has no expertise in industry regulation.”

Former commissioners of the center would “understand regulatory frameworks and the underlying principles of drug development”, noted Janet Woodcock. “Clearly, she doesn’t have the sort of resume that former directors who headed the center have had.”

The drug center has an enormous workload at the agency, the former commissioner pointed out.

“Many people just pays attention on the novel medication approvals, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and other areas, and all of those have to be supervised,” Dr. Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a major leadership aspect to the position, which oversees over 5,000 employees. “It is a huge leadership role, if you do it right,” the former official concluded.

Agency Reaction and Disputed Initiatives

When asked about concerns about Dr. Høeg's fitness for the role and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a press secretary responded that the “questions stem from inaccurate premises”.

“Her experience aligns with the duties of her job,” the representative stated, pointing to the months Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg inherits the agency head's controversial priority voucher program, a contentious rapid therapy clearance system that allegedly troubled her preceding directors. “How are these drugs being picked for this fast-track system? Who takes the decisions?” Howard asked. “There is a lot of confidentiality occurring at the regulatory body right now.”

In general, he remarked, “the agency seems to be moving towards less stringent oversight of pharmaceuticals, except for vaccines.”

Established History on Immunizations

With vaccines, Dr. Høeg has a more established, if concerning, past, critics observe. She authored a study using unconfirmed public submissions to assess the rate of heart inflammation after COVID-19 immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Among her “policy goals” for the incoming administration encompassed changing guidelines for recently developed shots and discontinuing “unnecessary” immunizations, she stated following the vote on a online show. At the agency, Høeg has allegedly floated the idea of barring young men from receiving Covid vaccinations.

“She is an all-around dogmatist who commences with her beliefs and reverse-engineers to retrofit the data in a extremely deceptive, dishonest manner,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow dissenters, {like|